What Is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate the pituitary gland to produce more growth hormone (GH). It comes in two forms that differ significantly in their pharmacokinetics and, consequently, their dosing protocols.

CJC-1295 with DAC (Drug Affinity Complex) includes a lysine linker that binds to serum albumin, extending its half-life to approximately 6 to 8 days. CJC-1295 without DAC, also known as Modified GRF (1-29), has a half-life of approximately 30 minutes, producing short, pulsatile bursts of GH release.

Because these two forms behave so differently in the body, their dosing schedules, frequencies, and clinical considerations are distinct. This guide covers both.

CJC-1295 with DAC: Dosage Protocols

Standard Dosing Range

In published clinical research, CJC-1295 with DAC has been studied at doses ranging from 30 mcg/kg to 60 mcg/kg of body weight, administered as a single subcutaneous injection. In clinical practice, most physicians prescribe a fixed dose rather than a weight-based calculation.

Common clinical dosing ranges include:

• 1,000 mcg (1 mg) once weekly: A conservative starting dose used for initial assessment of tolerability.
• 2,000 mcg (2 mg) once weekly: A commonly used maintenance dose that has produced significant GH and IGF-1 elevations in clinical studies.
• 2,000 mcg (2 mg) twice weekly: Used in some protocols for patients seeking more robust GH elevation, though this increases the potential for side effects.

Timing Considerations

Because the DAC form has a multi-day half-life, injection timing is less critical than with the non-DAC form. Most physicians recommend a consistent weekly schedule. Some practitioners suggest evening administration to complement the natural nocturnal GH surge, though the sustained-release nature of the DAC form means GH elevation persists regardless of injection time.

Cycle Length

Protocols for CJC-1295 with DAC vary, but many physicians prescribe it in cycles of 8 to 12 weeks, followed by a washout period of 4 to 8 weeks. Cycling helps prevent receptor desensitization and allows the physician to reassess lab work and clinical response before continuing therapy.

CJC-1295 Without DAC (Mod GRF 1-29): Dosage Protocols

Standard Dosing Range

The non-DAC form is cleared from the body much faster, requiring more frequent dosing to maintain its effects. Typical protocols include:

• 100 mcg per injection: A starting dose often used for sensitive individuals or those new to peptide therapy.
• 100 to 200 mcg per injection, 2 to 3 times daily: A common maintenance protocol. Injections are typically spaced at least 3 hours apart.
• 200 to 300 mcg per injection, 1 to 3 times daily: Used in more aggressive protocols, particularly when combined with a GHRP like Ipamorelin.

Timing Considerations

Timing matters significantly for the non-DAC form. Because it triggers a short-lived GH pulse, strategic timing can maximize its effectiveness:

• Morning (fasted): GH release is enhanced in a fasted state. Many protocols call for a morning injection at least 30 minutes before eating.
• Post-exercise: A post-workout injection can amplify the natural GH surge that follows intense exercise.
• Before bed: An evening injection, taken at least 2 to 3 hours after the last meal, aligns with the body's largest natural GH pulse during early sleep.

The most common three-injection protocol targets all three windows: morning, post-exercise, and bedtime.

The Role of Fasting

Elevated blood sugar and insulin levels blunt GH release. For this reason, CJC-1295 without DAC is most effective when injected in a fasted or post-absorptive state. Most physicians recommend waiting at least 30 minutes after injection before eating, and injecting at least 2 hours after a meal containing carbohydrates or fats.

Combination Dosing: CJC-1295 and Ipamorelin

CJC-1295 without DAC is frequently paired with Ipamorelin, a growth hormone-releasing peptide (GHRP) that works through the ghrelin receptor. The two peptides act through different and complementary pathways, and their combined effect on GH release may be greater than either peptide alone.

A common combination protocol involves:

• CJC-1295 without DAC: 100 to 200 mcg
• Ipamorelin: 100 to 200 mcg
• Administered together in the same injection, 1 to 3 times daily

Combination dosing should always be determined by a physician who can evaluate your baseline labs, health history, and treatment goals.

Factors That Influence Dosing

Your physician will consider several factors when determining the appropriate CJC-1295 dose for your protocol:

• Baseline GH and IGF-1 levels: Individuals with significantly low baseline levels may respond to lower doses, while others may require more to reach therapeutic targets.
• Age: GH production declines with age. Older patients may need different dosing strategies than younger adults.
• Body composition: Body weight and lean mass can influence peptide distribution and response.
• Treatment goals: A patient focused on sleep and recovery may have a different protocol than one focused on body composition.
• Tolerability: Side effects like water retention, headache, or joint stiffness may necessitate dose reduction.
• Concurrent medications: Certain medications, including corticosteroids and thyroid hormones, can interact with the GH/IGF-1 axis and affect dosing decisions.

Reconstitution and Storage

CJC-1295 is supplied as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before use. Proper reconstitution is essential for accurate dosing:

• Use bacteriostatic water (not sterile water or saline) for multi-dose vials.
• Inject the water slowly down the inside wall of the vial. Do not shake the vial; gently swirl or roll it until the powder is fully dissolved.
• Once reconstituted, store the vial in the refrigerator at 2 to 8 degrees Celsius (36 to 46 degrees Fahrenheit).
• Reconstituted CJC-1295 should typically be used within 3 to 4 weeks.
• Never freeze reconstituted peptide solutions.

The amount of bacteriostatic water used determines the concentration per unit on the insulin syringe. Your pharmacy or physician will provide specific reconstitution instructions for your vial size.

Safety Considerations

Dosing accuracy is one of the most important safety factors in peptide therapy. Too little may produce no meaningful effect; too much increases the risk of side effects including water retention, joint pain, numbness, and potential glucose dysregulation.

Self-dosing without physician guidance is not recommended. Published clinical data provides useful reference ranges, but individual variation means that optimal dosing must be determined through clinical evaluation and ongoing monitoring.

Regular lab work, including GH, IGF-1, fasting glucose, and insulin levels, allows your physician to verify that your dose is producing the intended physiological response without exceeding safe thresholds.

How Form Blends Can Help

Form Blends takes the guesswork out of CJC-1295 dosing. When you begin a peptide therapy program with Form Blends, your physician reviews your medical history, orders baseline lab work, and designs a dosing protocol tailored to your physiology and goals.

Your protocol includes the specific formulation (with or without DAC), dose per injection, injection frequency, timing recommendations, and a monitoring schedule. As your therapy progresses, your physician adjusts your protocol based on lab results, symptom feedback, and clinical response.

All peptides are dispensed through licensed U.S. compounding pharmacies, ensuring accurate dosing, verified purity, and proper handling from pharmacy to patient.